|
| | Publication Year | Title | Author(s) |
| 1 | 5-Sep-2019 | Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature. | Gunjur, Ashray ; Klein, Oliver ; Kee, Damien ; Cebon, Jonathan S |
| 2 | 12-Nov-2018 | Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. | Mitchell, Emma L; Lau, Peter Kar Han; Khoo, Chloe; Liew, David F; Leung, Jessica; Liu, Bonnia ; Rischin, Adam; Frauman, Albert G ; Kee, Damien ; Smith, Kortnye; Brady, Benjamin; Rischin, Danny; Gibson, Andrew; Mileshkin, Linda; Klein, Oliver ; Weickhardt, Andrew; Arulananda, Surein; Shackleton, Mark; McArthur, Grant; Östör, Andrew; Cebon, Jonathan S ; Solomon, Benjamin; Buchanan, Russell R C ; Wicks, Ian P; Lo, Serigne; Hicks, Rodney J; Sandhu, Shahneen |
| 3 | 2018 | Delayed Autoimmune Toxicity Occurring Several Months After Cessation of Anti-PD-1 Therapy. | Parakh, Sagun ; Cebon, Jonathan S ; Klein, Oliver |
| 4 | Jun-2017 | Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases | Parakh, Sagun ; Park, John J; Mendis, Shehara; Rai, Rajat; Xu, Wen; Lo, Serigne; Drummond, Martin; Rowe, Catherine; Wong, Annie; McArthur, Grant; Haydon, Andrew; Andrews, Miles C; Cebon, Jonathan S ; Guminski, Alex; Kefford, Richard F; Long, Georgina V; Menzies, Alexander M; Klein, Oliver ; Carlino, Matteo S |
| 5 | 11-Apr-2017 | Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''. | Bowyer, Samantha; Prithviraj, Prashanth; Lorigan, Paul; Larkin, James; McArthur, Grant; Atkinson, Victoria; Millward, Michael; Khou, Muoi; Diem, Stefan; Ramanujam, Sangeetha; Kong, Ben; Liniker, Elizabeth; Guminski, Alexander; Parente, Phillip; Andrews, Miles C; Parakh, Sagun ; Cebon, Jonathan S ; Long, Georgina V; Carlino, Matteo S; Klein, Oliver |
| 6 | 1-Feb-2017 | Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. | Menzies, A M; Johnson, D B; Ramanujam, S; Atkinson, V G; Wong, A N M; Park, J J; McQuade, J L; Shoushtari, A N; Tsai, K K; Eroglu, Z; Klein, Oliver ; Hassel, J C; Sosman, J A; Guminski, A; Sullivan, R J; Ribas, A; Carlino, M S; Davies, M A; Sandhu, S K; Long, G V |
| 7 | 10-May-2016 | Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. | Bowyer, S; Prithviraj, Prashanth; Lorigan, P; Larkin, J; McArthur, G; Atkinson, V; Millward, M; Khou, M; Diem, S; Ramanujam, S; Kong, B; Liniker, E; Guminski, A; Parente, P; Andrews, M C; Parakh, S ; Cebon, Jonathan S ; Long, G V; Carlino, M S; Klein, O |
| 8 | 7-Feb-2015 | Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma. | Klein, Oliver ; Davis, Ian D; McArthur, Grant A; Chen, Li; Haydon, Andrew; Parente, Phillip; Dimopoulos, Nektaria; Jackson, Heather M; Xiao, Kun; Maraskovsky, Eugene; Hopkins, Wendie; Stan, Rodica; Chen, Weisan; Cebon, Jonathan S |
| 9 | 1-Jun-2011 | Melanoma vaccines: developments over the past 10 years. | Klein, Oliver ; Schmidt, Christopher; Knights, Ashley J; Davis, Ian D; Chen, Weisan; Cebon, Jonathan S |
Loading...
2
0
20
0
false